Trends in Anesthesiology

The U.S. Food and Drug Administration (FDA) has approved Tibsovo (ivosidenib) for the treatment of adult patients with relapsed or refractory myelodysplastic syndromes (MDS) who have an isocitrate dehydrogenase-1 (IDH1) mutation. MDS is a rare form of blood cancer caused by mutations in bone marrow cells, leading to a deficiency of healthy blood cells. Tibsovo is the first targeted therapy approved for this specific indication, and it is used in conjunction with the Abbott RealTime IDH1 Assay, which is a companion diagnostic for identifying patients with the IDH1 mutation. The effectiveness of Tibsovo for this purpose was evaluated in an open-label, single-arm, multicenter study of 18 adult patients who were given 500 milligrams of Tibsovo orally daily for 28-day cycles, with positive outcomes, including a complete remission rate of 39% in patients. Sixty-seven percent of patients who required transfusions of blood or platelets due to MDS at the start of the study no longer required transfusions after treatment with Tibsovo. Tibsovo was previously approved for other conditions, such as acute myeloid leukemia and cholangiocarcinoma. This development is a significant advancement in the treatment of rare blood cancers and offers hope to patients with relapsed or refractory MDS who have the IDH1 mutation.Top of Form

Source: asamonitor.pub/3SGX2CL